Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer
Cancer Medicine · 2026
DOI: 10.1002/cam4.71548 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Keiso Ho und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Fibrinogen, Esophageal Neoplasms, Immune Checkpoint Inhibitors, Tumor Microenvironment. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation.
Abstract (Originalsprache)
Background
Plasma fibrinogen (FNG) is a prognostic marker in esophageal squamous cell carcinoma (ESCC). However, its predictive value for immune checkpoint inhibitor (ICI) efficacy and the underlying mechanisms remain unclear. This study aimed to evaluate the clinical significance of plasma FNG levels in ICI‐treated ESCC patients and investigate its association with tumor‐associated neutrophils (TANs) and genomic alterations.
Methods
A retrospective, multicenter analysis of 167 ESCC patients treated with ICIs was performed. TANs were quantified via immunohistochemistry using CD11b and CD66b staining, and PD‐L1 expression was assessed using the tumor proportion score (TPS). Whole‐exome and RNA sequencing were conducted to analyze genomic and transcriptomic profiles.
Results
Elevated plasma FNG levels correlated with lower ICI response rates and decreased survival. In first‐line treatment, chemo‐ICI therapy demonstrated superior efficacy compared to dual‐ICI therapy in high‐FNG patients, while the reverse trend was observed in low‐FNG patients. High‐FNG tumors showed increased TAN infiltration, independent of PD‐L1 expression. RNA sequencing revealed enrichment of neutrophil activation and extravasation pathways in high‐FNG tumors.
Conclusions
Elevated plasma FNG levels predict poor prognosis and reduced ICI efficacy in ESCC. They may be potential biomarkers for first‐line ICI‐based therapy and correlate with TAN infiltration. Further validation and mechanistic investigations are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
- Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
- Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Satoru Matsuda, Yuki Saito, Yasunori Kogure
Förderung
- Japan Society for the Promotion of Science
- Takeda Science Foundation
Zitieren
APA
Ho, K., Matsuda, S., Booka, E., Soneda, W., Okui, J., Hoshino, S., Takeuchi, M., Fukuda, K., Horie, S., Saito, Y., Kogure, Y., Kawakubo, H., Hara, K., Okita, H., Kataoka, K., Sekine, S., Takeuchi, H., & Kitagawa, Y. (2026). Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71548
Vancouver
Ho K, Matsuda S, Booka E, Soneda W, Okui J, Hoshino S, et al. Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.71548
BibTeX
@article{Ho2026,
author = {Ho, Keiso and Matsuda, Satoru and Booka, Eisuke and Soneda, Wataru and Okui, Jun and Hoshino, Shota and Takeuchi, Masashi and Fukuda, Kazumasa and Horie, Sara and Saito, Yuki and Kogure, Yasunori and Kawakubo, Hirofumi and Hara, Kensuke and Okita, Hajime and Kataoka, Keisuke and Sekine, Shigeki and Takeuchi, Hiroya and Kitagawa, Yuko},
title = {Plasma Fibrinogen Predicts Response to Immune Checkpoint Inhibitor by Inflammatory Tumor Microenvironment in Esophageal Cancer},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71548}
}
EUVIMED